StockMarketWire.com - Pharmaceutical giant AstraZeneca said its diabetes drug Forxiga had been approved in Japan to treat patients with chronic heart failure.

The approval was based on positive results from the DAPA-HF phase 3 trial published in The New England Journal of Medicine.

Additionally, Forxiga was currently being tested for heart failure patients with preserved ejection fraction in the DELIVER phase 3 trial with data readout anticipated in the second half of 2021, the company said.

Story provided by StockMarketWire.com